Chemomab Therapeutics (CMMB) Change in Accured Expenses (2018 - 2023)
Chemomab Therapeutics posted quarterly Change in Accured Expenses of $416000.0 for Q4 2023, up 137.31% year-on-year from $175298.6 in Q4 2022, and down 17.46% on a QoQ basis from $504000.0 in Q3 2023.
Chemomab Therapeutics (CMMB) has 6 years of Change in Accured Expenses data on file, last reported at $416000.0 in Q4 2023.
- For the quarter ending Q4 2023, Change in Accured Expenses rose 137.31% year-over-year to $416000.0; the trailing twelve-month figure through Dec 2023 stood at $45000.0 (down 95.04% YoY), and the FY2025 full-year result was -$1.2 million, up 36.3% from the prior year.
- Change in Accured Expenses for Q4 2023 stood at $416000.0, down from $504000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.1 million in Q2 2022 and bottomed at -$1.1 million in Q4 2022.
- The 5-year median for Change in Accured Expenses is -$40000.0 (2021), against an average of $18300.0.
- The widest annual swing landed in 2019, when Change in Accured Expenses jumped 437.73%; it then sank 6094.44% in 2022.
- A 5-year view of Change in Accured Expenses shows it stood at $922000.0 in 2019, then plunged by 68.0% to $295000.0 in 2020, then sank by 106.1% to -$18000.0 in 2021, then tumbled by 6094.44% to -$1.1 million in 2022, then surged by 137.31% to $416000.0 in 2023.
- The last three Change in Accured Expenses figures came in at $416000.0 (Q4 2023), $504000.0 (Q3 2023), and -$661000.0 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 416,000.00 |
| Dec 31, 2023 | 416,000.00 |
| Sep 30, 2023 | 504,000.00 |
| Sep 30, 2023 | 504,000.00 |
| Jun 30, 2023 | -661,000.00 |
| Jun 30, 2023 | -661,000.00 |
| Mar 31, 2023 | -214,000.00 |
| Mar 31, 2023 | -214,000.00 |
| Dec 31, 2022 | -1.12 Mn |
| Dec 31, 2022 | -1.12 Mn |
| Sep 30, 2022 | 865,000.00 |
| Sep 30, 2022 | 865,000.00 |
| Jun 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 13,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | -18,000.00 |
| Dec 31, 2021 | -18,000.00 |
| Sep 30, 2021 | -268,000.00 |
| Sep 30, 2021 | -268,000.00 |
| Jun 30, 2021 | -931,000.00 |
| Jun 30, 2021 | -931,000.00 |
| Mar 31, 2021 | -62,000.00 |
| Mar 31, 2021 | -62,000.00 |
| Dec 31, 2020 | 295,000.00 |
| Dec 31, 2020 | 295,000.00 |
| Sep 30, 2020 | 67,000.00 |
| Sep 30, 2020 | 67,000.00 |
| Jun 30, 2020 | 248,000.00 |
| Jun 30, 2020 | 248,000.00 |
| Mar 31, 2020 | -218,000.00 |
| Mar 31, 2020 | -218,000.00 |
| Dec 31, 2019 | 922,000.00 |
| Dec 31, 2019 | 922,000.00 |
| Sep 30, 2019 | -87,000.00 |
| Sep 30, 2019 | -87,000.00 |
| Jun 30, 2019 | -314,000.00 |
| Jun 30, 2019 | -314,000.00 |
| Mar 31, 2019 | -220,000.00 |
| Mar 31, 2019 | -220,000.00 |
| Dec 31, 2018 | -273,000.00 |
| Dec 31, 2018 | -273,000.00 |
| Sep 30, 2018 | -771,000.00 |
| Sep 30, 2018 | -771,000.00 |